Table 1 Key questions used to develop the guideline

1- Who are the targeted population?

2- What is the definition of typical KD, incomplete KD, atypical KD, and acute phase of KD?

3- What are the features of high-risk disease/severe disease?

4- What are the predictors for the development of coronary artery aneurysms and risk factors for IVIG resistance?

5- What is the definition of refractory/resistant KD?

6- How should KD patients assess and monitored and what is the frequency of monitoring KD?

7- What is the initial treatment of acute KD?

8- What is the initial treatment for patients with acute KD who are at high risk of IVIG resistance or developing coronary artery aneurysms?

9- What is the treatment for patients with acute KD resistant to treatment (refractory KD)?

10- What is the treatment for patients with acute KD who have arthritis resistance after IVIG treatment and who do not have coronary artery aneurysms KD?

11- What is the management of the ophthalmologic manifestation of KD?

12- What is the treatment for patients with incomplete KD?

13- What is the maintenance treatment in a patient with KD after an acute attack (treatment of cardiac complication)?

14- What is the prevention and treatment of thrombosis in patients with coronary aneurysms?

15- What is the treatment for patients with acute KD and complicated with macrophage activation syndrome?

16- What about vaccinations in a child with KD?

17- What is the long-term follow-up?